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Abstract
Ovarian tumor progression is marked by the peritoneal accumulation of leukocytes. Among these leukocytes, an
immunosuppressive CD11b+CD11c+ population has been identified in both human and ovarian tumors. The use
of transplantable models of murine ovarian tumors has demonstrated that this population promotes ovarian tumor
growth, whereas elimination of this population has been shown to inhibit ovarian tumor progression. Despite the
demonstrated importance of these cells to ovarian tumor progression, the mechanisms by which these cells are
recruited to the peritoneal tumor are largely unknown. Therefore, this study analyzes the mechanisms these cells
use to migrate to the peritoneum with the goal of therapeutically blocking their recruitment and subsequent im-
munosuppressive activity. Recent studies have identified that CX3CR1, Gr-1, and CCR2 delineate phenotypic and
functional murine monocyte subsets. Here, we report that CX3CR1
loGr-1hi cells dominate the population of perito-
neal CD11b+ leukocytes early in murine tumor development; however, the CX3CR1
hi population of cells present in
the peritoneum dramatically increases in both total numbers and percentage during tumor progression. Functional
analyses reveal that both of these CX3CR1 subsets are immunosuppressive to naive CD8
+ and CD4+ T-cell re-
sponses. Importantly, we demonstrate that CCR2 is a critical functional facilitator of leukocyte recruitment to
the ovarian tumor microenvironment, and its genetic deletion results in a reduced tumor burden compared with
wild-type mice. These results demonstrate that subsets of immunosuppressive leukocytes are recruited to the
ovarian tumor environment through the CCR2 pathway, which offers a viable therapeutic target to inhibit their mi-
gration to the tumor site.
Neoplasia (2009) 11, 564–573
Introduction
Peritoneal ovarian cancer recruits a prolific influx of leukocytes to the
tumor microenvironment [1,2]. Previous analyses have revealed that
high levels of leukocyte infiltration into the tumor microenviron-
ment are associated with a poor clinical prognosis [3–6]. Emerging
data on the function of these leukocytes now demonstrate that they
are co-opted by the tumor to foster tumor progression by supporting
angiogenesis and metastasis, functioning as myeloid-derived suppres-
sor cells (MDSCs) to suppress antitumor T-cell responses, and to
alter cytokine expression to create a tolerogenic milieu [3,7–18]. Re-
cent data from our laboratory and from others, using independent
methods, have demonstrated the importance of the CD11c+ leu-
kocytes to ovarian cancer by showing that their selective depletion
therapeutically inhibits the ID8 murine model of peritoneal ovar-
ian cancer [2,12,19]. These tumor-infiltrating CD11c+ cells are also
F4/80+CD11b+ and represent a population of cells variably referred
to as vascular leukocytes, tumor-associated macrophages, and im-
mature dendritic cells [2,10,14,20,21]. Despite the demonstrated
importance of these cells to ovarian tumor progression, the mecha-
nisms by which these cells are recruited to the peritoneal tumor are
largely unknown.
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Recent data indicate that the massive influx of these CD11c+ cells
are derived from the peritoneal macrophage pathway and are rem-
iniscent of elicited macrophage recruitment after induced peritoneal
inflammation [22]. In support of this was the finding that these
F4/80+CD11c+ cells supplant the canonical F4/80+CD11c− perito-
neal macrophage population and that these cells continue to express
CD115 [10]. This led us to hypothesize that the CD11c+ leukocytes
are monocyte-derived cells that are recruited to the peritoneal ovarian
tumor microenvironment through mechanisms by which peritoneal
macrophages are elicited and, importantly, that inhibition of recruit-
ment of these leukocytes would retard tumor progression.
In these studies, we have used the CX3CR1/CCR2/Gr-1 clas-
sification of murine monocytes to define the CD11b+ ovarian
tumor–recruited monocyte-derived cells both by phenotype and by
function. Murine monocyte subsets have recently been delineated
based on a high or a low expression of the fractalkine receptor,
CX3CR1. These subsets are further divided by expression of
CCR2 and Gr-1 into “inflammatory” (CX3CR1
loCCR2hiGr-1hi) or
“resident” (CX3CR1
hiCCR2loGr-1lo) populations based on their
preferential recruitment to sites of inflammation or noninflamed
tissue and relative life span in tissue [23]; human monocytes have
been analogously divided into the CX3CR1
loCD14hi and CX3
CR1hiCD14loCD16hi subsets, respectively [23,24]. We show that
after an initial recruitment of CX3CR1
lo monocytes, the tumor mi-
croenvironment is subsequently and progressively dominated by a
higher percentage and number of CX3CR1
hi leukocytes. Our previ-
ous data demonstrated that the tumor-associated CD11b+ leukocytes
are highly immunosuppressive to T-cell activity and that eradication
of the CD11b+SRA+ population of leukocytes inhibited tumor pro-
gression [10,19]. Here, we provide the first functional analyses of
the relative immunosuppressive activities of the two CX3CR1 sub-
sets and demonstrate that both subsets are immunosuppressive to
naive T-cell responses. Because clinical ovarian tumors and ID8 mu-
rine ovarian tumor cells express high levels of the CCR2 ligand
MCP-1 [1,25–27], and CCR2 mediates the recruitment of monocyte/
macrophages to peritoneal inflammation in response to MCP cytokines
[28], we tested the role of CCR2 in the context of ovarian tumor re-
cruitment of leukocytes. Here, we demonstrate that CCR2 is a critical
functional facilitator of leukocyte recruitment to the ovarian tumor
microenvironment and, correspondingly, that loss of CCR2 function
(CCR2−/−) is sufficient to substantially reduce numbers of infiltrating
leukocytes and to concomitantly inhibit ovarian tumor progression.
These studies provide new insight into the origins and phenotypes of
tumor-associated leukocyte populations, the mechanisms that they use
to migrate to the site of tumor growth, and the tumor dependence on
leukocyte presence and function.
Materials and Methods
Mice
Female C57Bl/6 mice were purchased from the National Cancer
Institute (Fredricksburg, MD). CCR2 knockout mice [29] and
CX3CR1-GFP [30] mice were purchased from Jackson Laboratories
(Bar Harbor, ME). All animal experiments were approved by the Dart-
mouth Medical School Institutional Animal Care and Use Committee.
Cells and Antibodies
ID8 cells transduced with Vegf-A and Defβ29 (referred to as ID8
within this manuscript) and ID8-Vegf cells transduced with green
fluorescent protein (ID8-C3) were obtained from Dr. Jose Conejo-
Garcia (Dartmouth Medical School). Cells were generated and main-
tained as previously described [2,31]. Anti–mouse Fc-Block and
anti–mouse CD11c (HC3) were purchased from BD Biosciences
(San Jose, CA). Anti–mouse F4/80 (BM8), anti–mouse CD3 (145-
2C11), anti–mouse Ly-6 (Gr-1) (RB6-8C5), anti–mouse CD45
(30-F11), and anti–mouse CD11b (M1/70) were purchased from
eBioscience (San Diego, CA). Anti–mouse CCR2 (E68) was pur-
chased from Novus Biologicals (Littleton, CO) and Zenon AlexaFluor
647 labeling kit was purchased from Invitrogen (Carlsbad, CA).
Anti–mouse CD45 (30-F11) was purchased from BioLegend (San
Diego, CA).
RNA Isolation and Reverse Transcription–Polymerase
Chain Reaction
Total RNAwas isolated from FACS-sorted CX3CR1 subsets isolated
out of blood and ascites from tumor-bearing mice using RNeasy
mini columns (Qiagen, Valencia, CA). RNA was quantified through
spectrophotometric analysis, and samples were treated with TURBO
DNase (Ambion, Austin, TX) to eliminate DNA contamination. RNA
was then used as template for cDNA synthesis using a Sensiscript RT
kit (Qiagen) and oligo DT primers. Polymerase chain reaction (PCR)
analysis was carried out using SYBR Green Supermix (Bio-Rad,
Hercules, CA) with primers designed to amplify products specific
for Ly6C (Gr-1) mRNA. Primers for Ly6C were as follows: reverse
5′-ACTTACCCAGCAGGGGCTAT-3′ and forward 5′-GCCTCTG-
ATGGATTCTGCAT-3′. Cycling conditions were initial denaturation
for 2 minutes at 94°C and 34 cycles for 45 seconds at 94°C, 1 minute
at 55°C, and 1 minute at 72°C, and a final extension for 2 minutes
at 72°C. Reverse transcription–polymerase chain reaction (RT-PCR)
for β-actin [32] was carried out in parallel; amplifications were also
performed in the absence of RTas a negative control. Polymerase chain
reaction products were analyzed by gel electrophoresis.
Tumor and Leukocyte Isolation
Ovarian tumors were generated by intraperitoneal (i.p.) injection
of 5 × 106 ID8 or ID8-C3 cells as previously described [2]. At the
indicated time points, ascites and blood were harvested from mice,
and the plasma and cellular fractions were collected. Red blood
cells were removed from the cellular fraction using ACK lysis buffer
(0.15 M NH4Cl, 1.0 mM KHCO3, 0.1 mM EDTA). Cells were
resuspended in 0.5% BSA in PBS or medium for subsequent analysis
or sorting. FACS sorting: Cells from mouse ascites and blood were
resuspended in 0.5% BSA in PBS and incubated with Fc blocking
antibody (clone 2.4G2) before staining with the indicated antibodies.
Flow cytometry and cell sorting were done on a FACS Calibur, FACS
Canto, or FACS Aria. Flow data were analyzed using Cellquest (BD
Biosciences) and FlowJo 8.8.4 software (FlowJo, Ashland, OR). Plasma
collected from tumor samples was analyzed for cytokine and chemo-
kine content using the luminex mouse 23-plex panel by the Immune
Monitoring Laboratory at Dartmouth Medical School (Norris Cotton
Cancer Center).
Immunosuppression Assays
A modified Lyons-Parish assay (described previously [10]) was
used to assess T-cell proliferation. Sorted cell populations from naive
and tumor-bearing mice were cocultured at a 1:10 ratio with 106
naive splenocytes obtained by passing spleen through a 70-μm cell
Neoplasia Vol. 11, No. 6, 2009 Monocyte Subsets and Functions in Ovarian Cancer Hart et al. 565
strainer (BD Biosciences). Single-cell suspensions were treated with
ACK lysis buffer to remove red blood cells and were resuspended
in 2.5 μM carboxyfluorescein succinimidyl ester (CFSE) in Hank’s
balanced salt solution. Splenocytes were incubated at 37°C for 10 min-
utes and washed twice with HBSS. Plated splenocytes were stimu-
lated with 1 μg of anti-CD3 (145-2C11), and culture supernatants
were collected after 72 hours and analyzed for interferon gamma
(IFN-γ) production using the murine DuoSet ELISA (R&D Systems,
Minneapolis, MN). Splenocytes from the Lyons-Parish assay were
stained for either CD4 or CD8, and CFSE dilution was determined
by FACS analysis. T-cell proliferation was quantitatively assessed with
the FlowJo Division Index, which is the average number of divisions
a cell within the population has undergone. In indicated experiments,
cell populations were incubated with 1 mM of the ARG1 inhibitor
hydroxy-nor-L-arginine (nor-NOHA; Calbiochem, San Diego, CA)
for 60 minutes at 37°C and washed three times with HBSS before
coculturing with splenocytes.
Cytotoxicity Assays
Cultured ID8 cells were CFSE-labeled using the same protocol as
above and cultured in the presence or absence of CD11b+ leukocytes
(isolated through a positive selection using CD11b magnetic beads
(Miltenyi Biotec, Auburn, CA)) derived from ID8 tumor ascites.
The cells were cocultured 1:1 overnight and assayed for viability
using the Mitoprobe DiIC1(5) Assay Kit (Molecular Probes, Eugene,
OR). Cytotoxicity was additionally quantified by measuring the re-
lease of CFSE from the tumor cells, as measured by fluorescence
within the media.
Results
Analyses of CX3CR1-Expressing Leukocyte Subsets during
Ovarian Tumor Progression
We previously showed that the predominant population of immu-
nosuppressive leukocytes in the ascites of ID8 ovarian tumor–bearing
mice expresses CD11b, CD11c, and F4/80 and is derived from the
monocyte/macrophage lineage [10]. With the recent creation of a
transgenic mouse that expresses GFP from the CX3CR1 (fractalkine
receptor) locus, murine monocytes and monocyte-derived cells
have been divided into two major subsets based on CX3CR1-GFP
expression: the “inflammatory” CX3CR1
loGr-1hi and “resident”
Figure 1. ID8 ovarian tumor-bearing mice preferentially accumulate CX3CR1
+Gr-1lo monocyte-derived cells in the peritoneal tumor micro-
environment. Blood and peritoneal monocyte phenotypes were analyzed over a time course of ID8 tumor progression in CX3CR1
+/GFP
mice. (A, B) FACS plots from blood and peritoneal samples from naive and tumor-bearing (7 and 28 days after tumor cell injection, as
indicated) mice as assessed by CX3CR1 expression (GFP) and stained for Gr-1 (A) and CD11b (B). (C) Percentages of CX3CR1 subsets
as determined by FACS from peritoneum of early (7 days) and late (28 days) tumor-bearing mice. (D) A weekly time course analysis of
the total number of peritoneal CX3CR1
+Gr-1lo cells after ID8 tumor cell injection as determined by FACS. In panels (C) and (D), the SD of
n ≥ 4 mice is shown. Statistical significance (**P < .01) was determined by Student’s t test.
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CX3CR1
hiGr-1lo populations [23]. The use of this mouse allowed us
to analyze the subsets of monocyte-derived cells within the ovarian
tumor ascites and to define their relative contributions to the tumor
microenvironment. To assess both the absolute and relative numbers
of these monocyte-derived subsets within the ovarian tumor ascites
during ID8 tumor progression, cells from the blood and peritoneum
were collected at weekly intervals and analyzed for CX3CR1-GFP
and Gr-1 expression by flow cytometry. No appreciable differences
were observed in the percentages of the Gr-1lo or Gr-1hi CX3CR1-
GFP–positive monocytes in the blood among naive mice, mice with
early tumor development (day 7), and mice with later-stage (day 28)
tumors and discernable ascites (Figure 1A). However, there was a
massive accumulation of CX3CR1
hiGr-1lo cells, both in terms of per-
centage (Figure 1C ) and in total quantity (Figure 1D) over the course
of tumor progression in the ascites. A predominance of the human
CD14hiCD16lo population, the analogous subset to the murine
CX3CR1
hi subset, has previously been reported in clinical ascites, in-
dicating that the ID8 mouse model recapitulates human disease
[23,24,33]. However, in the context of inflammation, this was
somewhat unexpected because the Gr-1hi, rather than the Gr-1lo,
population has been reported to preferentially recruit to sites of
inflammation [23]. To confirm that the tumor-associated CX3CR1-
expressing cells are within the previously characterized CD11b+
leukocyte population, we stained for CD11b. The CX3CR1-GFP–
expressing cells in the blood and ascites of both naive and tumor-
bearing mice indeed express CD11b (Figure 1B). This demonstrates
that the CX3CR1
hiGr-1lo subpopulation of cells is predominant
among the CX3CR1-expressing cells in the murine tumor environ-
ment and is the majority of the CD11b+ leukocyte population re-
cruited during tumor development.
CX3CR1
lo Gr-1hi Monocytes from the Blood Convert to Gr-1lo
Cells within the Tumor Ascites
The observation that the predominant CX3CR1 population that
accumulates in the ascites of tumor-bearing mice was Gr-1lo whereas
previous studies have shown that Gr-1hi monocytes preferentially
recruit to inflammation in the peritoneum and dominate early
monocyte recruitment to the tumor-bearing peritoneum seemed some-
what surprising. To determine whether the accumulation of the
CX3CR1hiGr-1lo leukocyte population within the ascites of tumor-
bearing mice was exclusively from selective recruitment of this mono-
cyte population in the blood or whether other monocyte subsets
could be converted to this phenotype, CX3CR1
hiGr-1lo (Figure 2A)
and CX3CR1
loGr-1hi (Figure 2B) blood monocyte subsets were sorted
and independently adoptively transferred i.p. to ID8 tumor-bearing
mice. Two days after transfer, ascites from recipient mice were har-
vested, stained for Gr-1, and analyzed by FACS for donor GFP+ cells.
CX3CR1-GFP–positive cells from recipient mice were almost entirely
Gr-1lo regardless of donor subset (Figure 2). This demonstrates that
CX3CR1lo monocytes decrease the expression of Gr-1 upon arrival
in the peritoneal tumor environment. Interestingly, the transferred
monocyte subsets maintain their CX3CR1 expression differences rela-
tive to one another as measured by mean fluorescence intensity
(Figure 2C ), albeit both sets of cells had slightly higher levels of
CX3CR1-GFP compared with their corresponding populations in
naive blood. This increase in CX3CR1 expression by monocytes trans-
ferred into the tumor microenvironment corresponds with recent
findings by Green et al. [34], which showed increased CX3CR1 expres-
sion after cellular stimulation. To determine whether the loss of cell
surface Gr-1 expression on the CX3CR1
lo subset was reflective of de-
creased gene expression, we FACS-sorted the Gr-1hi subset from the
blood and Gr-1lo subset from ascites of tumor-bearing mice (Figure 2B)
and performed RT-PCR to compare relative RNA expression of Gr-1.
The ascitic cells express lower levels of Gr-1 RNA than those isolated
from the blood (Figure 2E ). Thus, the decreased surface staining of
Gr-1 is likely due to a down-regulation of cellular expression of Gr-1.
Figure 2. CX3CR1
1oGR-1hi monocytes lose Gr-1 expression in the
peritoneal tumor microenvironment. (A) Gr-1loCX3CR1
hi and (B)
Gr-1hiCX3CR1
lo blood leukocyte subsets from naive mice were
FACS-sorted (left panels), and 105 cells from each population were
transferred in parallel into tumor-bearing mice by i.p. injection. Two
days after injection, peritoneal cells were recovered from recipient
mice and analyzed by FACS for Gr-1 expression on the GFP+ popula-
tion (right panels). (C) Themean fluorescence intensity of GFP expres-
sion of the CX3CR1
+ subsets, as indicated, from the blood of naive
mice (closed bars) and cells recovered from tumor-bearing recipient
mice after adoptive transfer (open bars) (n ≥ 3, SD shown). (D) As
a negative control, a tumor-bearing mouse that did not receive an
adoptive transfer of GFP+ cells was analyzed. (E) Gr-1hi blood and
Gr-1lo peritoneal CX3CR1
lo cells were sorted and analyzed by RT-
PCR for Gr-1 mRNA expression. β-Actin expression was used as an
expression-positive control; PCR was performed on samples without
RT (as indicated) as a negative control for DNA contamination.
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Analyses of the Tumor-Associated CX3CR1
+ Cellular Subsets to
Mediate T-cell Immunosuppression
Previous work has shown that the CD11b+ leukocyte population
that accumulates in the ascites suppresses T-cell activation and IFN-γ
production in response to mitogen stimulation [10]. The use of the
CX3CR1-GFP mouse allowed us to further divide the CD11b
+ pop-
ulation into distinct subsets, which may differ significantly in func-
tion and action within the tumor environment, and to ask whether
the observed immunosuppression is specific to one CD11b+ leuko-
cyte subset associated with the tumor or a summation of the multiple
subsets. Because the CX3CR1-GFP–positive cells in the tumor envi-
ronment are CD11b+ and contribute to the massive leukocyte infil-
tration within the ascites (Figure 1), we analyzed the relative ability of
the CX3CR1 subsets to functionally suppress naive T-cell responses.
CX3CR1
hi- and CX3CR1
lo-expressing cells from the ascites of
tumor-bearing mice were FACS-sorted and independently cocultured
with naive CFSE-labeled splenocytes. The T cells were subsequently
stimulated, and the CD4 and CD8 splenocyte populations were
analyzed for CFSE dilution as an indicator of proliferation. Both
CX3CR1
hi and CX3CR1
lo populations from tumor ascites signifi-
cantly suppressed naive CD4 (Figure 3A) and CD8 (Figure 3B) T-
cell proliferation. However, in the absence of any coculture or when
cultured with CX3CR1 subsets from the peritoneum of naive mice,
both CD4 (Figure 3D) and CD8 (Figure 3E ) T cells proliferated ro-
bustly. As a complementary assay to confirm the ability of the
CX3CR1 subsets to inhibit T-cell proliferation, the culture superna-
tants were analyzed for IFN-γ as a measure of splenocyte T-cell ac-
tivation. Both CX3CR1 subsets from tumor-bearing mice were able
to significantly (P < .01 for CX3CR1
lo; P < .005 for CX3CR1
hi) and
substantially suppress IFN-γ production (Figure 3C ) when com-
pared with splenocytes cultured alone or with CX3CR1 subsets from
naive mice (Figure 3F ). These results demonstrate that both subsets
of CX3CR1 cells in the ascites are capable of suppressing endogenous
T-cell responses and contribute to the immunosuppressive, tumor-
supporting environment in the peritoneum.
Previous work analyzing the immunosuppressive mechanism of the
entire population of CD11b+ leukocytes from the ascites of tumor-
bearing mice demonstrated that arginase-1 expression is required
by these leukocytes to suppress T-cell responses [10]. To determine
the role of arginase-1 in the immunosuppression mediated by the
Figure 3. Tumor-associated CX3CR1 subsets immunosuppress naive CD4
+ and CD8+ T-cell responses. CX3CR1
1o and CX3CR1
hi tumor-
associated leukocytes from the ascites of ID8 tumor-bearing CX3CR1
+/GFP mice were sorted by FACS. CX3CR1 -hi and -lo subsets were
independently assayed for immunosuppressive capability by a 72-hour coculture with CFSE-labeled, anti–CD3-stimulated, naive spleno-
cytes. CFSE dilution was used to calculate division indices for CD4+ (A) or CD8+ (B) T cells. (C) To confirm the CFSE analyses, super-
natants from stimulated naive splenocytes cocultured without (−) or with CX3CR1
+ subsets of cells (as indicated) were collected and
IFN-γ production was measured by ELISA. (D–F) As negative controls, the CX3CR1
+ peritoneal subsets from naive mice were FACS-
sorted and cocultured as in panels (A) to (C) to analyze their ability to suppress CD8 (D) and CD4 (E) proliferation as well as IFN-γ pro-
duction (F). Statistical significance is shown (**P < .01, ***P < .005).
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individual tumor-associated CX3CR1 cellular subsets, FACS-sorted
subsets from ID8 ascites were tested for their ability to inhibit naive
splenic T-cell proliferation after treatment with the specific arginase-1
inhibitor, nor-NOHA [35,36]. Suppression assays were performed as
in Figure 3 with untreated or nor-NOHA–treated CX3CR1 cells,
using T-cell proliferation as an experimental end point to quantita-
tively measure suppression of T-cell responses. Consistent with the
data from Figure 3, both CX3CR1 subsets potently inhibited T-cell
proliferation. However, preincubation with nor-NOHA was suf-
ficient to alleviate both CX3CR1
lo and CX3CR1
hi immunosuppres-
sion on CD4+ (Figure 4A) and CD8+ (Figure 4B) T-cell responses.
This demonstrates that arginase-1 activity is required for functional
immunosuppression of T-cell responses by both CX3CR1 subsets
and that blockade of arginase-1 activity abrogates this effect.
Genetic Deletion of CCR2 Reduces Tumor-Infiltrating
Leukocytes within the Ascites
In a previous work, we provided evidence that the CD11b+ leuko-
cytes that accumulate in the ascites of tumor-bearing mice are re-
cruited through the monocyte/macrophage pathway [10]. Work by
Boring et al. [29] established that monocyte/macrophage migration
to inflammation in the peritoneum requires CCR2 signaling, and
furthermore, human and murine (including the ID8 model) ovarian
cancers produce the CCR2 ligand MCP-1 [1,25–27]; our Luminex
analyses supported the previous reports from human ovarian ascites
and the ID8 ovarian tumor model [25–27,37,38] with the finding
that ID8 ascites consistently contains robust MCP-1 concentrations
between 758 and 4140 pg/ml. This evidence, along with our obser-
vation that the CX3CR1loGr-1
hi monocyte population, known to ex-
press CCR2, can undergo conversion to the cells found in the ascites,
led us to hypothesize that CCR2 expression is critical to the migra-
tion of leukocytes to the tumor site and that blocking this pathway
could reduce accumulation of tumor-promoting leukocytes.
FACS analyses revealed that both blood (Figure 5A) and peritoneal
(Figure 5B) murine CD11b+ leukocytes exhibited surface expression
of CCR2, and the CD11b+ cells were the predominant population
that expressed CCR2; leukocytes from CCR2−/− mice were stained in
parallel as a negative control (Figure 5C ). To test the functional contri-
bution of CCR2 to the recruitment of peritoneal tumor-infiltrating
leukocytes, wild-type (C57BL/6) and CCR2 knockout mice were in-
jected i.p. with ID8 ovarian tumor cells, and after tumor progression,
the subsequent leukocyte populations within the peritoneal ascites
were analyzed by FACS. CCR2 knockout mice exhibited significantly
reduced numbers of leukocytes, confirmed by F4/80+ (Figure 5D)
and CD11b+ (Figure 5E ) expression, within the peritoneal tumor
microenvironment in comparison to wild-type mice. Thus, CCR2
functions to recruit leukocytes, shown to have a tumor-promoting
phenotype and function ([10] and Figure 3), to the ovarian tumor site.
These findings are consistent with reports from other systems that
have shown involvement of CCR2 signaling in the recruitment of
anti-inflammatory cell types, including MDSCs and tumor-associated
macrophages [39,40]. The evidence that CCR2 is involved in recruit-
ing leukocytes with potential to support tumor development led us
to test whether CCR2 ablation would influence the development
and growth of tumors.
CCR2 Deletion Inhibits ID8 Ovarian Tumor Growth
and Progression
Elimination of various tumor-associated leukocyte populations
through a variety of methods has been reported to be therapeutically
efficacious. Particularly relevant to the current studies is that SRA-
targeted killing of CD11b+F4/80+ leukocytes within the peritoneal
ovarian tumor ascites was previously reported to result in a signifi-
cant reduction in tumor burden [19]. Because the loss of CCR2
expression inhibits the recruitment of these CD11b+ monocyte/
macrophages to the murine ascites and because CD11b+ leukocytes
have been shown to be critical contributors to tumor progression in a
variety of tumor models, we tested the effect of loss of host CCR2
expression on ID8 ovarian tumor progression. CCR2−/− and wild-
type mice were injected in parallel with GFP-expressing ID8 cells
(referred to as ID8-C3 cells), and the tumors and ascites were sub-
sequently harvested 7 weeks later and quantitatively analyzed for
tumor burden by measurement of total cellularity (after red blood
cell lysis), GFP+ cell number, and peritoneal wall metastases. Ex vivo
analyses revealed that the CCR2 knockout mice had reduced total
cellularity in their peritoneal ascites compared with their wild-type
controls (Figure 6A). Importantly, the loss of host CCR2 expres-
sion resulted in a reduction of tumor burden within the ascites, as
assessed by FACS analyses for GFP+ tumor cells (Figure 6B). As a
Figure 4. Tumor-associated CX3CR1
+ leukocyte subsets require
arginase-1 to immunosuppress naive CD4+ and CD8+ T-cell re-
sponses. CX3CR1
1o and CX3CR1
hi tumor-associated leukocytes
from the ascites of ID8 tumor-bearing CX3CR1
+/GFP mice were
sorted by FACS. Sorted CX3CR1 -hi and -lo subsets were incubated
in the presence or absence of 1 mM nor-NOHA and subsequently
independently assayed (as indicated) for immunosuppressive capa-
bility by a 72-hour coculture with CFSE-labeled naive splenocytes.
White bars indicate unstimulated splenocytes, whereas black bars
indicate splenocytes stimulated during the coculture with anti-
CD3 antibody. CFSE dilution was used to calculate division indices
for (A) CD4+ or (B) CD8+ T cells. Statistical significance is shown
(**P < .01, ***P < .005).
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complementary and confirmatory assay to comparatively assess tu-
mor burden and to ensure that reduced tumor burden in the ascites
was not concomitant with increased tumor deposition on the peri-
toneal wall, we also quantitatively analyzed the accumulation of
metastases on the peritoneal walls. After peritoneal lavage and ascites
harvest, the skin of the peritoneal walls of the wild-type and CCR2−/−
tumor-bearing mice was measured for GFP (tumor) fluorescence.
CCR2 knockout mice had fewer metastases than wild-type mice
both quantitatively (Figure 6C ) and qualitatively (Figure 6D), with
a ∼40% reduction in solid metastatic tumor burden on the peritoneal
walls. These data indicate that CCR2 is required for normal leuko-
cyte recruitment and is an integral part of peritoneal tumor progres-
sion and growth. In addition, these results specifically identify CCR2
as a potential route of therapeutic intervention for peritoneal ovarian
tumors and, in the broader picture, support an emerging body of data
that reduction of the number of tumor-associated leukocytes from the
microenvironment is an efficacious and viable therapeutic option.
Discussion
The presence of tumor-associated leukocytes is emerging as a vital
requirement for tumor progression. Increased leukocyte infiltration
of tumors has been reported to correlate with poor clinical progno-
sis, and correspondingly, recent studies in a variety of models have
demonstrated that reduction or elimination of leukocyte popula-
tions in the tumor microenvironment can inhibit the growth of
tumors [12,19,35,39,41–43]. The predominant leukocyte popula-
tion in ovarian cancer is the CD11b+CD11c+ leukocytes, which
are immunosuppressive to naive T-cell responses [10]. However,
the relation of these cells to circulating monocyte subsets and the
mechanisms by which these leukocytes are recruited to the tumor
site have not previously been defined. The observation that the pre-
dominant ovarian tumor–associated CD11b+CD11c+ leukocyte
population is derived from the CD115+CD11b+F4/80+ peritoneal
macrophage pathway [10] led us to hypothesize that these tumor-
associated leukocytes are recruited from the blood monocyte popula-
tions and that we could use the mice that express CX3CR1-GFP,
with the recent delineation of monocyte-derived cells into CX3CR1
-hi and -low populations, to determine the relative presence and the
functional contributions of these populations within the ovarian tu-
mor environment.
With the use of the murine ID8 ovarian tumor model, we dem-
onstrate that both CX3CR1
lo and CX3CR1
hi monocyte-derived
cells are present in the peritoneum during tumor progression. The
CX3CR1lo cells dominate the population of peritoneal CD11b
+ leu-
kocytes early in tumor development; however, the CX3CR1
hi popu-
lation of cells present in the peritoneum dramatically increases in
both total numbers and percentage and overtakes the CX3CR1
lo
population during tumor progression. The observation that the
CX3CR1
hi population dominates as tumors develop is consistent
with findings by Auffray et al. [44] that CX3CR1
hi monocytes re-
spond to tissue damage and preferentially differentiate into macro-
phages. In addition, we demonstrate that the CX3CR1
lo Gr-1hi
Figure 5. Loss of CCR2 inhibits leukocyte recruitment to ID8 peritoneal ascites. Cells from the blood (A) and peritoneum (B) of wild-type
(C57Bl/6) mice were stained for CD11b and CCR2 and analyzed by FACS. As a control, CCR2 expression on the CD11b+ cells from WT
(gray histograms) mice was compared with the respective cells from CCR2−/− (empty histograms) mice (A and B, inlaid). (C) CCR2−/−
cells were used as a control for antibody specificity and demonstrate that CCR2 is primarily expressed on the CD11b+ cells (blood
sample shown). (D, E) ID8 tumor-bearing wild-type and CCR2−/− mice were analyzed in parallel by FACS for F4/80+ and CD11b+ leu-
kocyte infiltration. A comparison of wild-type and CCR2−/− peritoneal F4/80+ (D) and CD11b+ (E) leukocyte population numbers 6 weeks
after tumor cell injection. The statistical significance (**P < .01, ***P < .005) of the CCR2−/− deficit was determined by Student’s t test
(WT n = 10, CCR2−/− n = 9).
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monocytes lose Gr-1 expression and increase CX3CR1 expression
upon adoptive transfer to the peritoneum, a phenomenon also re-
ported by Sunderkotter et al. [45] who observed the ability of some
Gr-1hi monocytes to convert to a Gr-1lo phenotype. Likewise, the
ability of CX3CR1
lo cells to convert to CX3CR1
hi cells within the ovar-
ian tumor microenvironment is consistent with the previous find-
ing that CX3CR1
lo monocytes can convert to CX3CR1
hi monocyte/
macrophages with an anti-inflammatory phenotype in a muscle injury
model [46]. Thus, our data support that “inflammatory” mono-
cytes recruited to the tumor site can convert their phenotype and
contribute to the growing CX3CR1
hi population observed during tu-
mor progression.
The massive recruitment of CX3CR1 monocytes to the perito-
neum in ovarian tumor-bearing mice indicated to us that these cells
were likely promoting tumor growth rather than inhibiting it or
being cytotoxic to the tumor cells (Figure W1). This is supported
by the work of Hagemann et al. [21], which showed that macro-
phages are polarized to a tumor-associated phenotype upon exposure
to ovarian cancer cells, and by the aforementioned work of Arnold
et al. [46], which reported that CX3CR1
lo monocytes can adopt an
anti-inflammatory phenotype. Moreover, we have shown that the
sum total of CD11b+ leukocytes from the peritoneum of tumor-
bearing mice contribute to tumor growth, in part through suppres-
sion of T-cell immune responses [10,19]. Here, we use CX3CR1-GFP
Figure 6. CCR2 knockout mice have reduced ovarian tumor burden. Wild-type and CCR2−/− mice were injected in parallel with ID8-C3
(GFP-expressing) tumor cells, and the ascites (A, B) and peritoneal wall (C) samples were subsequently harvested. CCR2−/−mice exhibit
a significant deficit in the total numbers of cells (after red blood cell lysis) in the ascites (A) and the number of the GFP+ tumor cells (B)
within the ascites relative to wild-type mice. (C) Peritoneal wall samples were collected from the WT and CCR2−/− tumor-bearing mice,
and GFP fluorescence was imaged using a Xenogen imaging system. (D) The mean GFP fluorescence per pixel from the samples in (C)
was quantified. SDs and statistical significance (*P < .05, **P < .01) are shown.
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mice to provide the first assessment of the relative immunosuppres-
sive abilities of the two specific CX3CR1 subpopulations by mea-
suring each for their ability to functionally suppress naive T-cell
responses. We demonstrate that both CX3CR1
lo and CX3CR1
hi leu-
kocytes from the peritoneum of tumor-bearing mice potently sup-
press naive T-cell proliferation and activation. Interestingly, whereas
the CX3CR1
hi population of cells shares CD11b expression and the
immunosuppressive properties of canonical murine MDSCs, it lacks
the robust Gr-1 expression normally observed on MDSCs. However,
the CD11b+CX3CR1
lo monocytes in the blood of tumor-bearing
mice express robust Gr-1 and we have now demonstrated that they
lose expression of Gr-1 upon entering the peritoneal tumor microen-
vironment. These data indicate that MDSCs may decrease in Gr-1
expression upon entering the tumor environment yet retain their im-
munosuppressive properties. This may provide an explanation for
why both CD11b+Gr-1hi and CD11b+Gr-1lo cells function similarly
to immunosuppress T cells and, moreover, would indicate that anal-
yses of MDSC populations solely by CD11b/Gr-1 staining may vary
greatly depending on the stage of the tumor and the percentage of
Gr-1hi cells that have converted to Gr-1lo expression.
One paradigm of tumor growth is that it results in low-level in-
flammation, likely the result of tissue invasion, angiogenesis, cytokine
production, and immune cell infiltration [20,47,48]. An important
chemokine that mediates the recruitment of immune cells to sites of
inflammation, is known to be produced by human and murine ovar-
ian cancer cells, and is a CCR2 agonist is MCP-1 [1,25–27]. This
along with our previous observation that the CD11b+ cells recruited
to ovarian tumors are likely the product of the peritoneal macro-
phage pathway led us to hypothesize that, analogous to the influx
of CD11b+ leukocytes elicited by other forms of peritoneal inflam-
mation, CCR2 may play a critical functional role in monocyte
recruitment to the ovarian tumor microenvironment. If correct, this
hypothesis would also support the previous observation that CCR2-
expressing CX3CR1
lo monocytes are recruited from the blood to
peritoneal inflammation and other sites of inflammation. Here, we
show that, in accord with other models of peritoneal inflammation,
leukocyte recruitment to the peritoneal tumor microenvironment is
dependent on CCR2 expression and loss of the receptor inhibits
accumulation of the CD11b+ and F4/80+ cell population(s). Impor-
tantly, we demonstrate that prevention of CCR2-dependent cell re-
cruitment to the peritoneum results in inhibition of ovarian tumor
progression as assessed by the quantity of tumor cells within the
ascites and in solid metastases upon the peritoneal wall (Figure 6).
These findings identify CCR2 as a key mediator to the recruitment
of immunosuppressive leukocytes to peritoneal ovarian cancer. More-
over, they support the emerging concept derived from a variety of
tumor models that tumor-associated leukocytes are critical to tumor
progression and that, correspondingly, inhibition or removal of these
leukocytes can inhibit tumor growth.
In summary, these findings provide insight into the monocyte
origin and the mechanisms of recruitment of ovarian tumor-associated
leukocyte populations that provide immunosuppressive support for
tumor growth and progression. Identification of the monocyte/
macrophage pathway as a principal route of leukocyte recruitment
to the tumor site has important implications for therapeutic inter-
vention in the accumulation of these leukocytes and provides a
number of potential approaches for blocking their supportive role
in tumor development. Specifically, these studies implicate CCR2
as the predominant mechanism by which ovarian tumors recruit
tumor-promoting monocyte-derived cells to the peritoneum. Our
findings derived from the CCR2−/− mouse lead us to propose that
blockade of CCR2 activity in ovarian cancer may have therapeutic
potential and that this strategy may improve the efficacy of other cur-
rently used treatment regimens.
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Figure W1. ID8 tumor-associated CD11b+ leukocytes are not cytotoxic to ID8 tumor cells. (A) ID8 cells were CFSE-labeled and cultured
in the presence (black line) or absence (gray line) of CD11b+ leukocytes isolated from ID8 tumor ascites. The cells were cocultured
overnight and assayed for viability with the Mitoprobe assay. Loss of viability is reflected in decreased cell-associated Mitoprobe fluo-
rescence; positive control is shown (shaded). (B) Cytotoxicity was additionally quantified by measuring the release of fluorescence from
CFSE-labeled ID8 tumor cells, in the absence (ID8) and presence (+CD11b) of CD11b+-isolated ascitic leukocytes (as in (A)), and by
measuring CFSE fluorescence within the supernatant.
